TABLE 2.
Description of clinical outcomes (mean Myasthenia Gravis Activities of Daily Living [MG‐ADL] score, number and percentage of exacerbations, myasthenia gravis crisis, minimal symptoms expression and Myasthenia Gravis Foundation of America [MGFA] class) during the biannual study follow‐up periods.
| Clinical outcome | Baseline (N = 220) | Year 1–2 (N = 219) | Year 3–4 (N = 164) | Year 5–6 (N = 124) | Year 7–8 (N = 94) |
|---|---|---|---|---|---|
| Mean MG‐ADL score (SD) | 5.04 (3.17) | 1.56 (2.30) | 1.09 (1.83) | 1.15 (2.06) | 0.7 (1.40) |
| Minimal symptom expression, n (%) | NA | 141 (64.4) | 115 (70.0) | 82 (66.1) | 69 (73.4) |
| Exacerbations in 2 years, n (%) a | NA | 112 (30.1) | 54 (23.8) | 28 (22.6) | 20 (20.2) |
| Myasthenic crisis in 2 years, n | NA | 7 | 3 | 2 | 1 |
| MGFA class, n (%) | |||||
| Asymptomatic | NA | 104 (47.1) | 95 (57.9) | 79 (63.7) | 63 (67) |
| I | 77 (35.0) | 18 (8.1) | 15 (9.1) | 10 (8.1) | 7 (7.4) |
| IIA | 48(21.8) | 59 (26.9) | 33 (20.1) | 22 (17.7) | 18 (19.1) |
| IIB | 58 (26.4) | 25 (11.4) | 14 (8.5) | 10 (8.1) | 5 (5.3) |
| IIIA | 7 (3.2) | 6 (2.7) | 3 (1.8) | 2 (1.6) | 1 (1.1) |
| IIIB | 17 (7.7) | 4 (1.8) | 4 (2.4) | 1 (0.8) | 0 |
| IVA | 1 (0.5) | 1 (0.5) | 0 | 0 | 0 |
| IVB | 9 (4.1) | 1 (0.5) | 0 | 0 | 0 |
| V | 3 (1.4) | 0 | 0 | 0 | 0 |
Abbreviations: MG‐ADL, Myasthenia Gravis Activities of Daily Living; MGFA, Myasthenia Gravis Foundation of America; NA, not applicable; SD, standard deviation.
a
Percentage of patients experiencing exacerbations.